Business Context and Reporting Period
Company: Creative Medical Technology Holdings, Inc. (CELZ)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2024
Business Overview: A commercial-stage biotechnology company focused on immunotherapy, endocrinology, urology, neurology, and orthopedics. The company markets CaverStem® and FemCelz® kits for sexual dysfunction and is developing stem cell therapies for Type 1 Diabetes (CELZ-201 CREATE-1) and chronic lower back pain (CELZ-201 ADAPT). The company is classified as a smaller reporting company and non-accelerated filer.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenues | $0 | $6,000 | $8,000 | $6,000 |
| Net Loss | $(1,040,135) | $(1,453,952) | $(3,639,407) | $(3,608,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.75) | $(1.02) | $(2.59) | $(2.55) |
| Operating Expenses | $1,109,674 | $1,546,785 | $3,862,927 | $3,851,893 |
| Cash and Cash Equivalents (Ending) | $6,260,438 (as of Sept 30, 2024) | |||
| Total Assets | ||||
| Total Liabilities | $330,908 (Current Liabilities only) | |||
| Stockholders' Equity | $6,557,011 |
Material Changes vs. Prior Period
- Revenue: Revenue was $0 for Q3 2024 compared to $6,000 in Q3 2023. YTD revenue increased slightly to $8,000 from $6,000.
- Net Loss: Net loss improved (decreased) by 28% in Q3 2024 compared to the prior year quarter. YTD net loss remained relatively flat, increasing slightly by 0.9%.
- Operating Expenses:
- R&D: Decreased 41% in Q3 2024 ($581,796 vs. $992,722) due to reduced general R&D, partially offset by increased spending on the CELZ-201 ADAPT clinical trial. YTD R&D increased 19% ($1.93M vs. $1.62M) driven by clinical trial costs for Diabetes and Lower Back Pain programs.
- SG&A: Decreased 6% in Q3 2024 ($498,607 vs. $531,042) and 15% YTD ($1.85M vs. $2.16M), driven by reductions in marketing, professional fees, and D&O insurance.
- Liquidity: Cash balance increased from $3.47M at year-end 2023 to $6.26M at Sept 30, 2024, primarily due to the redemption of $6.52M in investments (certificates of deposit/Treasuries).
- Investments: Investments dropped from $6.52M at Dec 31, 2023 to $0 at Sept 30, 2024, as they were redeemed to bolster cash reserves.
Outlook, Risks, and Unusual Items
- Clinical Progress:
- Received FDA Orphan Drug Designation for Brittle Type 1 Diabetes (March 2024).
- Initiated dosing for the Phase I/II clinical trial for Chronic Lower Back Pain (CELZ-201 ADAPT) in Q2 2024.
- Received FDA authorization for expanded access therapy to prevent Type 1 Diabetes in high-risk individuals (March 2024).
- Capital Raise (Subsequent Event): On October 22, 2024, the company closed a registered direct offering of 418,552 shares at $4.42 per share, raising approximately $1.6 million in net proceeds. Warrants were also issued to purchase up to 837,104 shares.
- Related Party Transactions:
- CEO purchased one share of Series B Preferred Stock for $100 in May 2024, granting 100 million votes specifically on proposals to increase authorized common stock.
- Payments of $200,000 were made in July/August 2024 to a related party (CMH) for patent milestones related to the StemSpine clinical trial.
- Risks: The company has a limited operating history, minimal revenue, and relies on external funding. Risks include the success of clinical trials, regulatory approvals, and the ability to raise capital. The company notes that cash balances exceed FDIC insurance limits at three institutions.
- Stock Repurchases: The company continued its share repurchase program, buying 8,250 shares in Q3 2024 at an average price of $2.94. Cumulative YTD repurchases totaled 43,750 shares.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $6.26M cash balance and the $1.6M raised in the October 2024 offering to determine operational runway.
- Clinical Trial Milestones: Monitor the progress and results of the CELZ-201 ADAPT (Lower Back Pain) and CELZ-201 CREATE-1 (Type 1 Diabetes) trials, as these are the primary drivers for future valuation.
- Revenue Generation: Assess the commercial viability of the CaverStem® and FemCelz® kits, given the negligible revenue reported ($8,000 YTD).
- Dilution Impact: Review the terms of the October 2024 offering, including the 837,104 warrants issued, to understand potential future dilution.
- Related Party Obligations: Review future payment obligations under the StemSpine and ImmCelz licensing agreements with related parties (CMH and Jadi Cell).